O
XERS icon

OrbiMed’s Xeris Biopharma Holdings XERS Stock Holding History

OrbiMed’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80,420
Closed -$655K – 130
2025
Q3 		$655K Hold
80,420
– – 0.02% 106
2025
Q2 		$376K Hold
80,420
– – 0.01% 100
2025
Q1 		$442K Hold
80,420
– – 0.01% 109
2024
Q4 		$273K Hold
80,420
– – 0.01% 118
2024
Q3 		$229K Hold
80,420
– – ﹤0.01% 118
2024
Q2 		$181K Hold
80,420
– – ﹤0.01% 113
2024
Q1 		$178K Buy
+80,420
New +$208K ﹤0.01% 114

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OrbiMed's XERS Position: Q4 2025 in Review

OrbiMed sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 80,420 shares — an estimated $655K sold.

OrbiMed first reported a position in XERS in Q1 2024 and held it in 7 quarters. The position peaked at $655K in Q3 2025. 224 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • OrbiMed reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • OrbiMed sold 80,420 Xeris Biopharma Holdings shares in Q4 2025, an estimated $655K.
  • OrbiMed first reported a position in Xeris Biopharma Holdings in Q1 2024 and held it in 7 quarters.
  • OrbiMed's Xeris Biopharma Holdings position peaked at $655K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.